ABCL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

6.28M

+23.21%

-0.190

+58.33%

14.43M

+240.66%

-0.185

+23.33%

16.66M

-2.49%

-0.175

+45.83%

Estimates Revision

The market is revising Upward the revenue expectations for AbCellera Biologics Inc. (ABCL) for FY2025, with the revenue forecasts being adjusted by 4.49% over the past three months. During the same period, the stock price has changed by -30.46%.

Revenue Estimates for FY2025

Revise Upward

+4.49%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+6.97%

In Past 3 Month

Stock Price

Go Down

-30.46%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast ABCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABCL is 5.50 USD with a low forecast of 4.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

4.00

Averages

5.50

High

7.00

Current: 0.000

Low

4.00

Averages

5.50

High

7.00

Leerink

Outperform -> Market Perform

downgrade

2025-11-07

Reason

Leerink

Price Target

2025-11-07

downgrade

Outperform -> Market Perform

Reason

Leerink downgraded AbCellera to Market Perform from Outperform with a $4 price target.

BMO Capital

Outperform

maintain

$5 -> $7

2025-08-08

Reason

BMO Capital

Price Target

$5 -> $7

2025-08-08

maintain

Outperform

Reason

BMO Capital raised the firm's price target on AbCellera to $7 from $5 and keeps an Outperform rating on the shares after its Q2 earnings beat. While previous quarters in recent memory have been more challenged for AbCellera as the company has attempted to transition to an internal development clinical biotechnology company, Q2 earnings highlighted positive updates with the addition of '688 as a new development candidate and initial clinical data for '635 expected in mid-2026, the analyst tells investors in a research note.

Leerink

Outperform

initiated

2025-07-07

Reason

Leerink

Price Target

2025-07-07

initiated

Outperform

Reason

Leerink assumed coverage of AbCellera with an Outperform rating and $5 price target. The firm likes AbCellera's pivot from being an antibody discovery platform company to developing their own internal pipeline, and it sees potential for ABCL575 in atopic dermatitis and ABCL635 in vasomotor symptoms. Both programs are up-and-coming agents with validated mechanisms in large commercial opportunities.

Truist

Buy

downgrade

$28 -> $10

2025-05-16

Reason

Truist

Price Target

$28 -> $10

2025-05-16

downgrade

Buy

Reason

Truist lowered the firm's price target on AbCellera to $10 from $28 and keeps a Buy rating on the shares. The firm has updated its model after the company's Q1 results, though it continues to be positive about AbCellera, highlighting its continued execution of their wholly owned clinical pipeline, and given the company's hybrid business model with a focus shifting towards a clinical stage biotech, Truist is also updating its discount rate to reflect the transition, the analyst tells investors in a research note.

Stifel

Stephen Willey

Buy

downgrade

$10 -> $8

2025-05-09

Reason

Stifel

Stephen Willey

Price Target

$10 -> $8

2025-05-09

downgrade

Buy

Reason

Stifel analyst Stephen Willey lowered the firm's price target on AbCellera to $8 from $10 and keeps a Buy rating on the shares. The firm views the unveiling of NK3R as the target of ABCL635 ahead of the Phase 1 trial initiation as "an interesting development which positions ABCL635 as a more-selective/likely-safer and more-convenient treatment option," the analyst tells investors following management's earnings announcement and corporate update.

Keybanc

Scott Schoenhaus

Buy

Maintains

$4 → $5

2025-04-16

Reason

Keybanc

Scott Schoenhaus

Price Target

$4 → $5

2025-04-16

Maintains

Buy

Reason

KeyBanc raised the firm's price target on AbCellera to $5 from $4 and keeps an Overweight rating on the shares. Into Q1 earnings, the firm believes the focus for the HCIT sector will be on legislative policies, healthcare system utilization, and macro concerns on a slowing economy paired with potentially higher inflation. While valuations in HCIT land remain discounted vs. healthcare more broadly, KeyBanc thinks investors should be focused on companies that can drive meet/beats over the next 12 months. Specifically, it sees the least risk from a revenue and earnings perspective from companies that are well positioned in the more stable healthcare end markets serving the payers and large pharma.

Valuation Metrics

The current forward P/E ratio for Abcellera Biologics Inc (ABCL.O) is -4.76, compared to its 5-year average forward P/E of 9.90. For a more detailed relative valuation and DCF analysis to assess Abcellera Biologics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

9.90

Current PE

-4.76

Overvalued PE

55.46

Undervalued PE

-35.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

7.18

Current EV/EBITDA

-2.86

Overvalued EV/EBITDA

63.50

Undervalued EV/EBITDA

-49.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

29.80

Current PS

18.51

Overvalued PS

46.32

Undervalued PS

13.28

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ABCL News & Events

Events Timeline

No data

News

7.0

2025-12-18SeekingAlpha

AbCellera resolves patent dispute with Bruker regarding microfluidic technology.

1.0

2025-12-08Newsfilter

AbCellera to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

5.0

2025-12-01NASDAQ.COM

Insider Buying Update for Monday, December 1: DASH, ABCL

People Also Watch

Frequently Asked Questions

What is Abcellera Biologics Inc (ABCL) stock price today?

The current price of ABCL is 4.11 USD — it has decreased -0.48 % in the last trading day.

What is Abcellera Biologics Inc (ABCL)'s business?

AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

What is the price predicton of ABCL Stock?

What is Abcellera Biologics Inc (ABCL)'s revenue for the last quarter?

Abcellera Biologics Inc revenue for the last quarter amounts to 8.96M USD, increased 37.62 % YoY.

What is Abcellera Biologics Inc (ABCL)'s earnings per share (EPS) for the last quarter?

Abcellera Biologics Inc. EPS for the last quarter amounts to -0.19 USD, increased 11.76 % YoY.

What changes have occurred in the market's expectations for Abcellera Biologics Inc (ABCL)'s fundamentals?

How many employees does Abcellera Biologics Inc (ABCL). have?

Abcellera Biologics Inc (ABCL) has 596 emplpoyees as of January 09 2026.

What is Abcellera Biologics Inc (ABCL) market cap?

Today ABCL has the market capitalization of 1.23B USD.